Dulaglutide is a GLP-1 agonist used to manage type 2 diabetes mellitus.

Brand Names
Generic Name
DrugBank Accession Number

Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM).5 Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations.8

Approved, Investigational
Biologic Classification
Protein Based Therapies
Fusion proteins / Hormones
Protein Structure
Protein Chemical Formula
Protein Average Weight
59669.81 Da
> Dulaglutide Sequence
Download FASTA Format
  • Dulaglutida
  • Dulaglutide
External IDs
  • LY-2189265



Dulaglutide is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years of age with type 2 diabetes mellitus.7 It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.7

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofMajor adverse cardiovascular events••••••••••••••••••••••••••••••• •••••••••••••
Prevention ofMajor adverse cardiovascular events•••••••••••••••••••••••••••• •••••••••••••• ••••••••••••••••
Adjunct therapy in management ofType 2 diabetes mellitus•••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Dulaglutide reduces fasting glucose concentrations and reduces postprandial glucose (PPG) concentrations in patients with type 2 diabetes mellitus through the agonism of the GLP-1 receptor.7 This drug primarily acts as an incretin mimetic hormone or analog of human glucagon-like peptide-1, which normally acts on the GLP-1 receptor.6

Mechanism of action

Dulaglutide activates the GLP-1 receptor found in pancreatic beta cells, increasing intracellular cyclic AMP (cAMP) in beta cells, leading to insulin release and subsequent reduction of blood glucose concentrations. Additionally, dulaglutide decreases glucagon secretion and slows gastric emptying.6,7

AGlucagon-like peptide 1 receptor

Dulaglutide is slowly absorbed after subcutaneous injection.9 In a pharmacokinetic study of 20 healthy adults, Cmax occurred within 24-48 hours after dosing.3 The average absolute bioavailability of dulaglutide after subcutaneous injections of single 0.75 mg and 1.5 mg doses was 65% and 47%, respectively.7

Volume of distribution

The apparent volume of distribution of dulaglutide was 3.09 L in a pharmacokinetic study; the apparent population mean peripheral volume of distribution was approximately 6 L.7

Protein binding

Protein binding information for dulaglutide is not readily available in the literature.7,9


Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways.7

Route of elimination

Elimination of dulaglutide is expected to occur through degradation to individual amino acids.7


In a pharmacokinetic study of 20 healthy adults, the average half-life of dulaglutide administered at various doses was approximately 3.75 days (89.9 hours). This extended half-life allows for once-weekly dosing.3 Prescribing information indicates a half-life of approximately 5 days.7


The apparent population mean clearance of dulaglutide was 0.142 L/h in a pharmacokinetic study.7

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

LD50 information for dulaglutide is not readily available in the literature.10 Cases of overdose with dulaglutide have resulted in gastrointestinal disturbance. Appropriate supportive treatment is recommended to manage signs and symptoms.9 Additionally, hypoglycemia has been observed after an overdose with dulaglutide; frequent plasma glucose monitoring should be performed.7

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Dulaglutide.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Dulaglutide.
AcebutololThe therapeutic efficacy of Dulaglutide can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Dulaglutide can be increased when used in combination with Acetazolamide.
AcetohexamideDulaglutide may increase the hypoglycemic activities of Acetohexamide.
Food Interactions
  • Take with or without food.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
TrulicitySolution0.75 mg / 0.5 mLSubcutaneousEli Lilly & Co. Ltd.2016-01-08Not applicableCanada flag
TrulicityInjection, solution0.75 mgSubcutaneousEli Lilly Nederland B.V.2021-01-12Not applicableEU flag
TrulicityInjection, solution1.5 mg/0.5mLSubcutaneousA-S Medication Solutions2014-09-18Not applicableUS flag
TrulicityInjection, solution3.0 mg/0.5mLSubcutaneousEli Lilly and Company2020-09-03Not applicableUS flag
TrulicityInjection, solution3.0 mg/0.5mLSubcutaneousA-S Medication Solutions2020-09-03Not applicableUS flag


ATC Codes
A10BJ05 — Dulaglutide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Not Available
Organic Compounds
Super Class
Organic Acids
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Alternative Parents
Not Available
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number


General References
  1. Nadkarni P, Chepurny OG, Holz GG: Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014;121:23-65. doi: 10.1016/B978-0-12-800101-1.00002-8. [Article]
  2. Sanford M: Dulaglutide: first global approval. Drugs. 2014 Nov;74(17):2097-103. doi: 10.1007/s40265-014-0320-7. [Article]
  3. Amblee A: Mode of administration of dulaglutide: implications for treatment adherence. Patient Prefer Adherence. 2016 Jun 2;10:975-82. doi: 10.2147/PPA.S82866. eCollection 2016. [Article]
  4. Geiser JS, Heathman MA, Cui X, Martin J, Loghin C, Chien JY, de la Pena A: Clinical Pharmacokinetics of Dulaglutide in Patients with Type 2 Diabetes: Analyses of Data from Clinical Trials. Clin Pharmacokinet. 2016 May;55(5):625-34. doi: 10.1007/s40262-015-0338-3. [Article]
  5. Burness CB, Scott LJ: Dulaglutide: A Review in Type 2 Diabetes. BioDrugs. 2015 Dec;29(6):407-18. doi: 10.1007/s40259-015-0143-4. [Article]
  6. Smith LL, Mosley JF 2nd, Parke C, Brown J, Barris LS, Phan LD: Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist. P T. 2016 Jun;41(6):357-60. [Article]
  7. FDA Approved Drug Products: Trulicity (dulaglutide) subcutaneous injection [Link]
  8. AJMC: FDA Approves Dulaglutide for Adults With T2D, Regardless of CVD [Link]
  9. EMA Assessment Report: Trulicity (dulaglutide) solution for injection [Link]
  10. Eli Lilly MSDS: Trulicity (dulaglutide) [Link]
PubChem Substance
RxList Drug Page
Drugs.com Drug Page
Download (97.1 KB)

Clinical Trials

Clinical Trials
4Active Not RecruitingBasic ScienceAdiposity / Decreased carbohydrate and glucose tolerance / Effect of Drugs / Overweight and Obesity1
4Active Not RecruitingTreatmentHyperglycemia / Type 2 Diabetes Mellitus1
4Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
4CompletedOtherType 2 Diabetes Mellitus1
4CompletedTreatmentDiabetes Mellitus1


Not Available
Not Available
Dosage Forms
InjectionSubcutaneous0.75 mg
InjectionSubcutaneous1.5 mg
Injection, solutionParenteral; Subcutaneous0.75 MG
Injection, solutionParenteral; Subcutaneous1.5 MG
Injection, solutionParenteral; Subcutaneous3 MG
Injection, solutionParenteral; Subcutaneous4.5 MG
Injection, solutionSubcutaneous0.75 mg/0.5mL
Injection, solutionSubcutaneous1.5 mg/0.5mL
Injection, solutionSubcutaneous3 mg
Injection, solutionSubcutaneous3.0 mg/0.5mL
Injection, solutionSubcutaneous4.5 mg
Injection, solutionSubcutaneous4.5 mg/0.5mL
SolutionSubcutaneous0.75 mg / 0.5 mL
SolutionSubcutaneous1.5 mg / 0.5 mL
SolutionSubcutaneous1.500 mg
SolutionSubcutaneous3 mg / 0.5 mL
SolutionSubcutaneous4.5 mg / 0.5 mL
Injection, solutionSubcutaneous0.75 mg
Injection, solutionSubcutaneous1.5 mg
SolutionSubcutaneous0.75 mg
SolutionSubcutaneous1.5 mg
Injection, solution0.75 mg/0.5ml
Injection, solution1.5 mg/0.5ml
Not Available
Not Available


Experimental Properties
Not Available


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Pharmacological action
General Function
Transmembrane signaling receptor activity
Specific Function
This is a receptor for glucagon-like peptide 1. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
Gene Name
Uniprot ID
Uniprot Name
Glucagon-like peptide 1 receptor
Molecular Weight
53025.22 Da
  1. Sanford M: Dulaglutide: first global approval. Drugs. 2014 Nov;74(17):2097-103. doi: 10.1007/s40265-014-0320-7. [Article]
  2. Umpierrez G, Tofe Povedano S, Perez Manghi F, Shurzinske L, Pechtner V: Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014 Aug;37(8):2168-76. doi: 10.2337/dc13-2759. Epub 2014 May 19. [Article]
  3. Nadkarni P, Chepurny OG, Holz GG: Regulation of glucose homeostasis by GLP-1. Prog Mol Biol Transl Sci. 2014;121:23-65. doi: 10.1016/B978-0-12-800101-1.00002-8. [Article]
  4. Skrivanek Z, Gaydos BL, Chien JY, Geiger MJ, Heathman MA, Berry S, Anderson JH, Forst T, Milicevic Z, Berry D: Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5). Diabetes Obes Metab. 2014 Aug;16(8):748-56. doi: 10.1111/dom.12305. Epub 2014 May 22. [Article]
  5. Lorenz M, Lawson F, Owens D, Raccah D, Roy-Duval C, Lehmann A, Perfetti R, Blonde L: Differential effects of glucagon-like peptide-1 receptor agonists on heart rate. Cardiovasc Diabetol. 2017 Jan 13;16(1):6. doi: 10.1186/s12933-016-0490-6. [Article]
  6. Giorgino F, Benroubi M, Sun JH, Zimmermann AG, Pechtner V: Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2). Diabetes Care. 2015 Dec;38(12):2241-9. doi: 10.2337/dc14-1625. Epub 2015 Jun 18. [Article]
  7. Gallwitz B: Novel Therapeutic Approaches in Diabetes. Endocr Dev. 2016;31:43-56. doi: 10.1159/000439372. Epub 2016 Jan 19. [Article]
  8. Miyagawa J, Odawara M, Takamura T, Iwamoto N, Takita Y, Imaoka T: Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study. Diabetes Obes Metab. 2015 Oct;17(10):974-83. doi: 10.1111/dom.12534. Epub 2015 Aug 20. [Article]
  9. Htike ZZ, Zaccardi F, Papamargaritis D, Webb DR, Khunti K, Davies MJ: Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017 Apr;19(4):524-536. doi: 10.1111/dom.12849. Epub 2017 Feb 17. [Article]
  10. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z: Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014 Aug;37(8):2149-58. doi: 10.2337/dc13-2761. Epub 2014 Apr 17. [Article]
  11. Tamaki C, Takeuchi M, Iwamoto N, Glaesner W: [Pharmacological profile and clinical trial results of a long-acting, once weekly human GLP-1 receptor agonist Dulaglutide (Genetical Recombination)]. Nihon Yakurigaku Zasshi. 2015 Oct;146(4):215-24. doi: 10.1254/fpj.146.215. [Article]
  12. FDA Approved Drug Products: Trulicity (dulaglutide) subcutaneous injection [Link]

Drug created at April 29, 2015 18:08 / Updated at November 22, 2022 18:59